Drug Type Small molecule drug |
Synonyms Lisofylline (USAN/INN), A-802710, BL 194 + [4] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC13H20N4O3 |
InChIKeyNSMXQKNUPPXBRG-SECBINFHSA-N |
CAS Registry100324-81-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04748 | Lisofylline | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lung Injury | Phase 3 | US | - | - |
Chemotherapy-induced damage | Phase 3 | US | - | - |
Graft Rejection | Phase 3 | US | - | - |
Graft Rejection | Phase 3 | - | - | |
Graft Rejection | Phase 3 | - | - | |
Mucositis | Phase 3 | US | - | - |
Neutropenia | Phase 3 | US | - | - |
Diabetes Mellitus, Type 1 | Phase 2 | US | 01 May 2009 | |
Shock, Septic | Preclinical | US | - | - |
Multiple Sclerosis | Discovery | US | - |
Phase 1/2 | 1 | (Lisofylline Subcutaneous) | npjonqmvzc(vepgjxfufz) = hgfhuuefzr dsqvuohibl (oxsnonksys, ehajqtifbr - abwommiytn) View more | - | 18 Aug 2016 | ||
(Lisofylline Intravenous) | npjonqmvzc(vepgjxfufz) = ezsogndnpy dsqvuohibl (oxsnonksys, rjclwopgai - xrvcgrpnqk) View more |